Submit a final report containing data from clinical trials enrolling a sufficient representation of Black or African American patients that is reflective of the US population of patients with EGFR exon 20 insertion mutated NSCLC to further characterize the safety and efficacy of amivantamab-vmjw in Black or African American patients with EGFR exon 20 insertion mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.